1994 Clinical outcomes from EMERALD trial: A phase I evaluating ultra-hypofractionated MR-Guided Adaptive SABR (SMART) for localized pancreatic cancer.
2025 · Radiotherapy and Oncology · 0 citations
https://doi.org/10.1016/s0167-8140(25)00781-9
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
0
Papers
0
Citations
Lynda Swan is an academic researcher.
https://doi.org/10.1016/s0167-8140(25)00781-9
https://doi.org/10.1016/s0167-8140(25)01739-6
Click to start Chat